14% rise in Japan's FY2009 SS budget

12 January 2009

The fiscal year 2009 budget for Japan's Ministry of Health, Labor and Welfare's social security including pensions and medical and nursing  care increased 14% to 24,830.0 billion yen ($86.9 billion) compared to  the year earlier.

Within this: 213.9 billion yen was allocated to disease management, up  5.6%, of which: 22.5 billion yen goes to promoting countermeasures  against infectious diseases including a new type of influenza; and 158.7  billion yen for tackling intractable diseases. Projects for hepatitis  and the promotion of AIDS prevention will get 20.5 billion yen and 7.5  billion yen, respectively, and 1.1 billion yen was allocated for  rheumatic and allergic diseases.

23.7 billion yen and 8.6 billion yen, respectively, were earmarked for  cancer prevention and research, and measures against developing  diabetes and stroke, along with the promotion of women's health,  respectively. The budget for innovative drugs and medical devices was  raised by 1.1% to 27.7 billion yen. Within this, 25.1 billion yen has  been allocated for research into new advanced technologies including  regenerative medicine and personalized therapies, and 400.0 million  yen for establishing a world-class infrastructure for clinical research.  In addition, 920.0 million yen has been hypothecated for promoting  the use of generic drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight